














Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.		BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.	EU Nodes  	AZD1222	Core – EMA Non-COVAX	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Accepted core data of AZ – non-Covax	Core data – now as donation for COVAX.	1 st wk April 2021
							Data for Covax sites expected in April 2021 onwards	Awaited	April 2021 onwards
3.	SK BIO  	AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.	Serum Institute of India	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.		Ad26.COVS.2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	Core data (US +NL sites)	Finalized	12 March 2021
							Additional sites awaited	Awaited	To be fixed after data submission
6.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	Mid. April 2021
7.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	Mid. April 2021
8.		mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	In progress using the abridged procedure (EMA).	Mid. April 2021
9.		Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	“Rolling” submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Inspections in May and June 2021	Will be fixed after all data is submitted and inspections completed.
10.		Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting April 2021		
11.			EMA	No pre-submission meeting yet.	Submitted EOI on 23 Feb	To be planned in April based on company request.			
12.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
13.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.				

	Manufacturer	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
14.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
15.	 Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells					
16.	Bharat Biotech, India	COVAXIN	DCGI	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	Requested meeting to discuss details of submission/timelines				
17.	Clover Biopharmaceuticals	SCB-2019	EMA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	In discussion on submission strategy and timelines				
18.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	In discussion on submission strategy and timelines				

1. Beijing Bio-Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.